Rasio utang jangka cendhak marang ekuitas: Denali Therapeutics (DNLI)
The market price visualization for the DNLI ticker on the GURU.Markets platform demonstrates the 0.02 indicator. Denali Therapeutics brings together leading neurobiologists to create a research environment dedicated to combating degenerative brain pathologies. The company is developing innovative methods to cross the blood-brain barrier, providing it with a patent advantage and strategic interest from pharmaceutical behemoths in the therapy of Parkinson's and Alzheimer's diseases.
denalitherapeutics.com (DNLI) - rincian metrik lan laporan keuangan
- kuotasi lan prakiraan analis:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Denali Therapeutics|DNLI - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Denali Therapeutics Inc.|DNLI - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Denali|DNLI - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Denali Therapeutics|Likuiditas cepet denalitherapeutics.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
Analisis kabeh metrik perusahaan:DNLI Denali Therapeutics Inc
This ratio measures the proportion of short-term liabilities within the equity structure, allowing for an assessment of liquidity risk in the event of a sharp increase in payments. An analysis of the historical ratio of short-term loans to equity for Denali Therapeutics (DNLI) confirms the company's financial stability, as the development of its non-cyclical scientific research relies on strategic partnerships, minimizing dependence on macro-environment volatility.
Karo sapa Denali Therapeutics saingan
Utang jangka cendhak marang modal BIIB|NBIX - Kewajiban jangka cendhak marang modal|Regencell Bioscience - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal axsome.com AXSM|ACAD - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Utang jangka cendhak marang modal|Rasio utang jangka cendhak marang modal HRMY (harmonybiosciences.com)|Utang jangka cendhak marang modal BHVN|AMLX - Kewajiban jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Trevi Pharma TRVI|PRAX: Rasio utang jangka cendhak marang modal|Anavex Life Sciences - Utang jangka cendhak marang modal|CBLL - Utang jangka cendhak marang modal|Prothena Corp (PRTA) - Utang jangka cendhak marang ekuitas|ALEC (Alector) - Utang jangka cendhak marang ekuitas|ANNX (Annexon Inc.) - Utang jangka cendhak marang modal|Omeros Corp. (OMER) - Koefisien utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas NGNE (Neurogene Inc.)|ACIU (acimmune.com) - Rasio tanggungan utang jangka cendhak marang modal|Voyager Therapeutics, Inc. - Rasio utang jangka cendhak marang ekuitas|Rasio silihan jangka cendhak marang modal NMRA (Neumora)|Scilex Holding Co. - Utang jangka cendhak marang modal|Rasio tanggungan utang jangka cendhak marang modal TVGN (Tevogen Bio Inc.)|ACOG: Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal cogrx.com (CGTX)|Utang jangka cendhak marang ekuitas Inhibikase Therapeutics, Inc.|SAVA: Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang modal ASRT|Utang jangka cendhak marang modal coyatherapeutics.com (COYA)|Utang jangka cendhak marang ekuitas Vistagen VTGN|OVID (Ovid Therapeutics Inc) - Kewajiban jangka cendhak marang ekuitas|Acumen Pharmaceuticals, Inc. - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal CervoMed, Inc.|ATHE (alteritytherapeutics.com) - Rasio utang jangka cendhak marang ekuitas|Clene (CLNN) - Utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas PEPG|JUNS (jupiterneurosciences.com) - Rasio silihan jangka cendhak marang modal|Utang jangka cendhak marang modal RLMD|Koefisien utang jangka cendhak marang modal Annovis Bio Inc|Utang jangka cendhak marang modal GRCE (Grace Therapeutics)|AIFF - Rasio utang jangka cendhak marang ekuitas|KLTO - Utang jangka cendhak marang ekuitas|Koefisien utang jangka cendhak marang modal NeuroSense Therapeutics NRSN|RVPH: Utang jangka cendhak marang modal|Rasio utang jangka cendhak marang modal MTVA|Utang jangka cendhak marang ekuitas NeurAxis, Inc|Rasio utang jangka cendhak marang modal HSDT (Helius Medical Technologies Inc.)|Utang jangka cendhak marang ekuitas Passage Bio, Inc. (PASG)|Utang jangka cendhak marang ekuitas NEUP (bionomics.com.au)|Utang jangka cendhak marang modal NERV (Minerva Neurosciences, Inc.)|Koefisien utang jangka cendhak marang modal Athira Pharma Inc (ATHA)|ADXN - Utang jangka cendhak marang ekuitas|ALZN (Alzamend Neuro, Inc.) - Rasio utang jangka cendhak marang modal|CYCN: Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Protagenic Therapeutics, Inc. (PTIX)|Rasio utang jangka cendhak marang ekuitas KTTA|Utang jangka cendhak marang modal Cortigent Medical|Utang jangka cendhak marang ekuitas Avenue Therapeutics, Inc (ATXI)|BCLI (BrainStorm Cell Therapeutics Inc.) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Cara Therapeutics, Inc. CARA|chromocell.com (CHRO) - Kewajiban jangka cendhak marang modal|Eliem - Utang jangka cendhak marang modal|ITCI (Intra-Cellular Therapies) - Rasio utang jangka cendhak marang modal|LBPH: Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Marinus Pharma (MRNS)|Utang jangka cendhak marang ekuitas NKGen Biotech, Inc.|Rasio utang jangka cendhak marang modal NRBO (neurobopharma.com)|Utang jangka cendhak marang modal SAGE|Utang jangka cendhak marang modal Synaptogenix Inc. (SNPX)|Utang jangka cendhak marang ekuitas Trevena, Inc TRVN|Vigil Neuroscience Inc. - Utang jangka cendhak marang ekuitas|Anew Medical, Inc. - Utang jangka cendhak marang modal|Koefisien utang jangka cendhak marang modal cerevel.com CERE